Mirion Technologies Q2 2026 Earnings Call Transcript

Quartr
Provided by Quartr
July 29, 2026

Key Takeaways

  • Positive Sentiment: Orders and backlog remained strong, with Q2 orders up 10% organically and total backlog reaching more than $1.1 billion, nearly 40% above the prior year. Nuclear power orders grew approximately 50% excluding M&A, supported by both the operating fleet and small modular reactor opportunities.
  • Positive Sentiment: Mirion maintained its full-year 2026 guidance and expects a significant second-half acceleration, including 7.5%–11.2% organic revenue growth, roughly 27%–29% Adjusted EBITDA margins, and $95 million–$115 million of second-half adjusted free cash flow.
  • Positive Sentiment: Q2 revenue rose 20% to $266.8 million and Adjusted EBITDA increased 27.5% to $65 million, while margins expanded across both segments on favorable mix, pricing, and cost control. The company also repurchased approximately $25 million of shares during the quarter.
  • Neutral Sentiment: Medical performance was mixed: RTQA’s outlook was raised to double-digit organic growth, but nuclear medicine guidance was reduced to mid-single digits and dosimetry is now expected to decline for the year because of delayed hardware demand and difficult prior-year comparisons. Management characterized the nuclear medicine weakness as a delay rather than a structural decline.
  • Negative Sentiment: Mirion disclosed an unexpected cancellation of an $18 million Chinese new-build order originally booked in 2019, citing stalled project progress and geopolitical tensions. Management said the cancellation does not affect 2026 guidance and has only an immaterial impact on longer-term plans.
AI Generated. May Contain Errors.
Earnings Conference Call
Mirion Technologies Q2 2026
00:00 / 00:00

Transcript Sections

Skip to Participants
Operator

Greetings. Welcome to the Mirion Technologies second quarter 2026 earnings conference call. At this time, all participants are in a listen-only mode. A question-and-answer session will follow the formal presentation. If anyone should require operator assistance during the conference, please press star zero on your telephone keypad. Please note this conference is being recorded. I will now turn the conference over to Eric Linn, Treasurer and Head of Investor Relations. Thank you, Eric. You may begin.

Eric Linn
Eric Linn
Treasurer and Head of Investor Relations at Mirion Technologies

Hey. Thank you, Liz, and good morning, everyone. Welcome to Mirion's second quarter 2026 earnings conference call. Joining me this morning are Mirion's Founder, Chairman, and CEO, Tom Logan, and Mirion's CFO and Medical Group President, Brian Schopfer. Before we begin today's prepared remarks, allow me to remind you that comments made during this call will include forward-looking statements.

Eric Linn
Eric Linn
Treasurer and Head of Investor Relations at Mirion Technologies

Actual results may differ materially from those projected in the forward-looking statements. The factors that could cause actual results to differ are discussed in our annual reports on Form 10-K, quarterly reports on Form 10-Q, and in Mirion's other SEC filings under the caption Risk Factors. Quarterly references within today's discussion are related to the second quarter ended June 30th, 2026, unless otherwise noted. The comments made during this call will also include certain financial measures that were not prepared in accordance with generally accepted accounting principles.

Eric Linn
Eric Linn
Treasurer and Head of Investor Relations at Mirion Technologies

Reconciliation of those non-GAAP financial measures to the most directly comparable GAAP financial measures can be found in the appendix of the presentation accompanying today's call. All earnings materials can be found in the investor relations section of our website at www.mirion.com. With that, let me now turn the call over to Tom, who will begin on panel three.

Tom Logan
Tom Logan
Chairman and CEO at Mirion Technologies

Eric, thank you. Good day to everyone joining on the call today. Yesterday, after market close, we issued our second quarter results. Once again, we demonstrated growing orders and backlog, including key large opportunity order wins. This double-digit order growth is fueling continued backlog expansion as the nuclear power momentum continues to take hold. We also demonstrated expanding adjusted EBITDA margins from both operating segments and across the total enterprise. Better mix and pricing helped to more than offset the dilutive impacts from M&A and broader inflation headwinds. All of this is setting the stage for a strong second half 2026 acceleration. We're maintaining our 2026 full-year guidance, which implies a meaningful step-up in financial performance for the remainder of the year. Brian will walk you through the details, including expectations for the third quarter and the second half.

Tom Logan
Tom Logan
Chairman and CEO at Mirion Technologies

We continue to believe that the momentum in nuclear power is building. Nowhere is this more evident than right here in North America. As I've said on prior calls, the nuclear super trend continues to broaden, and this quarter's headlines, highlighted on panel four, make that abundantly clear. Here in the U.S., regulatory and policy improvements are supporting momentum within nuclear power.

Tom Logan
Tom Logan
Chairman and CEO at Mirion Technologies

The NRC has proposed updates designed to streamline the licensing process, eliminating unnecessary burdens and increasing regulatory clarity, while importantly maintaining safety standards. Pair that with the Department of Energy's $17.5 billion loan program to support new reactor builds, and you can see both the financing and regulatory gateways beginning to open up simultaneously. We're also encouraged by execution, not just policy. The DOE's reactor pilot program achieved criticality across four advanced reactor designs, outperforming its own target of three by the July 4th deadline.

Tom Logan
Tom Logan
Chairman and CEO at Mirion Technologies

That's a tangible example that small modular reactor designs are progressing. Importantly, Mirion, Paragon, and Certrec were squarely in the mix on each of these advanced reactor designs. On the demand side, new power deals continue to materialize. Constellation and Walmart announced a new nuclear power agreement, Walmart's first, and amongst the first between a large retailer and a nuclear facility in this country. Additionally, New York State and Canada are advancing their nuclear plans to add additional capacity. Moreover, just last week, the U.S. announced a deal with Saudi Arabia to supply new reactors and nuclear technology, creating another avenue of incremental nuclear demand. Each of these examples in just the past few months showcase the well-timed acquisitions of Paragon and Certrec to leverage their market-leading positions within North America.

Tom Logan
Tom Logan
Chairman and CEO at Mirion Technologies

Looking beyond North America on panel five, fresh data from the World Nuclear Association reinforces what we're already seeing take hold, a generational build-out of global nuclear capacity. Today, the world operates at approximately 400 gigawatts of nuclear capacity. Latest projections forecast a tripling of total global capacity by 2050 to nearly 1.5 terawatts. This is a 45% increase compared to projections a decade ago.

Tom Logan
Tom Logan
Chairman and CEO at Mirion Technologies

Even excluding growth from China and Russia, global capacity still grows at a staggering 2x. Each projection on this panel points in the same direction, increased demand for Mirion solutions and an expanding installed base that provides recurring demand for decades to come. Recall, approximately 80% of our nuclear power-based revenue comes from today's installed base and is the source of considerable recurring and repeat revenue. Panel six focuses on the near to medium-term. Reactors operating today are providing foundational demand growth.

Tom Logan
Tom Logan
Chairman and CEO at Mirion Technologies

At a high level, we're seeing three waves of installed base nuclear customer demand. The first wave is catch-up capital spending. Decades of capital rationing across the operating fleet left operators with a backlog of deferred maintenance and required replacement parts. Add in the funnel of plant restarts we've talked about, and you get an outsized near-term call on commercial-grade dedication, reverse engineering, and spare parts out of our Paragon platform. The second wave is life extensions and extended power upgrades. Once an operator makes the decision to life extend, they have greater visibility to operate for another 10 to 20 years. This triggers upgrade decisions to instrumentation and controls and broader plant ecosystems. The third wave is emerging, but it's coming. Digital transformation. The nuclear workforce is aging out, and with it goes decades of tribal knowledge.

Tom Logan
Tom Logan
Chairman and CEO at Mirion Technologies

Replacing these workers are digital natives increasingly looking toward digital platforms to capture and scale that expertise. Additionally, digital platforms are providing the firepower to optimize outages and assist operators in improving thermal efficiency. We're already seeing these factors drive order growth, as illustrated on panel seven. Second quarter 2026 backlog totals over $1.1 billion. This is nearly 40% higher versus a year ago. Legacy backlog, excluding backlog additions from the Paragon and Certrec deals, has grown by 17%. Let's drill into this legacy backlog number a bit to illustrate my broader point about growing nuclear power demand. This subset of the backlog has seen incredible growth, up 31% versus 17% for total legacy Mirion. If you isolate the legacy Mirion installed base, it's even more impressive, up nearly 40% versus Q2 2025. Panel eight addresses investor questions on the second half revenue visibility.

Tom Logan
Tom Logan
Chairman and CEO at Mirion Technologies

We continue to have good line of sight to our full-year revenue expectations. Between first half actual results and backlog expected to convert to revenue in the second half, approximately 81% of our expected full-year revenue is accounted for. Importantly, this 81% shows comparable revenue coverage to prior years. This gives us the confidence to maintain full-year revenue expectations. Additionally, Paragon's Peaks business adds a new revenue stream for us that does not appear in backlog. Instead, this revenue is booked in-quarter. Before I turn it over to Brian to detail the quarter, allow me to spend a minute on AI, shown on panel nine. This is where an increasing amount of my time is spent today, thinking strategically and guiding our business to harness the incredible potential from artificial intelligence.

Tom Logan
Tom Logan
Chairman and CEO at Mirion Technologies

We're investing to create early adopter advantage by embedding AI into how we develop products, how we serve customers, and how we run our operations. We've organized our AI strategy across three distinct pillars with dedicated resources committed to accelerating adoption and deployment across the company. The first pillar is accelerating product development. AI is fundamentally changing our software development cycles and compressing time to market. Specifically, we're improving data analytics, accelerating real-time feedback loops, and improving testing and compliance workflows that would have taken our engineering teams months to execute manually. The ability to move faster while maintaining, and in fact, improving the rigor of our compliance processes is a genuine game changer. The second pillar is organization-wide efficiencies. AI is becoming an important tool in this effort, from automating back-office processes like document review to test plan development.

Tom Logan
Tom Logan
Chairman and CEO at Mirion Technologies

We're still in the early innings here, but the trajectory is encouraging, and the internal adoption is gaining traction. The third pillar, the one I'm most excited about, is AI-powered solutions. We're developing new AI-centric innovations across both segments. Importantly, we are increasingly focused on connecting our hardware devices. Think instruments that sit in nuclear power plants and cancer treatment centers around the world to software and data platforms that drive measurable productivity improvements for our customers.

Tom Logan
Tom Logan
Chairman and CEO at Mirion Technologies

In fact, last week at the AAPM annual meeting in Vancouver, we highlighted our new Plan AI Dosimetry platform, which enables dosimetrists to deliver higher-quality patient-specific plans faster. In our RTQA business, we also highlighted our new Daily QA 4 Pro, which consolidates dosimetry and imaging checks into a single indexed imageable solution, reducing room entries, minimizing setup time, and standardizing execution across users. Importantly, it is integrated into our existing SunCHECK platform so physics teams can spend less time on logistics and more time on patient care. Let me turn it over now to Brian to walk through the financials. Brian?

Brian Schopfer
CFO and Medical Group President at Mirion Technologies

Thank you, Tom. Good morning, everyone. I'll continue the prepared remarks on slide 10, outlining our financial performance. Second quarter total revenue was $267 million, an increase of 20% versus last year's second quarter. Organic revenue growth was 1%, in line with our expectations and aligned with what we communicated in April. Second quarter adjusted EBITDA was $65 million or 27.5% higher than last year. Margins expanded 150 basis points in the quarter, driven by favorable product mix and price across both segments.

Brian Schopfer
CFO and Medical Group President at Mirion Technologies

Excluding the impacts of M&A and a one-time tariff refund, margins would have expanded over 200 basis points. We've received approximately $1 million in tariff refunds to date. Based on how the stock is traded, we used approximately $25 million of our $100 million share repurchase program in the second quarter to opportunistically buy back approximately 1.4 million shares.

Brian Schopfer
CFO and Medical Group President at Mirion Technologies

This brings our total share buybacks for the year to approximately $40 million, with $40 million still remaining under the program. We generated $49 million of adjusted free cash flow in the quarter, reflecting higher adjusted EBITDA and a source of cash from net working capital, as well as continued tailwinds from our refinancing activities last year. Lastly, as Tom outlined, orders in the second quarter were strong, up 10% versus last year's second quarter. Slide 11 details the continued progress against our large opportunity pipeline. In the second quarter, we won a number of opportunities, including the previously disclosed large SMR order at Paragon, the second part of another SMR order, another portion of the radioactive waste handling order within our defense and diversified end market.

Brian Schopfer
CFO and Medical Group President at Mirion Technologies

Slightly later than we had expected, we've continued to see good momentum as we turn the page to July, where in the first two weeks, we were awarded more than $50 million of large orders, including a large European installed base order and a U.S. Department of Energy order. In July, we also unexpectedly experienced a cancellation for a Chinese new build order that was originally booked in 2019. The sites that this project are associated with have seen little progress. These projects were stalled due to geopolitical tensions that started shortly after they were signed. Normally, with Chinese new builds, we see a much shorter order-to-build cycle. It is important to note that this project has no impact to our 2026 guidance and an immaterial impact on any of our long-range guides that we have given.

Brian Schopfer
CFO and Medical Group President at Mirion Technologies

In total, our July awards bring our year-to-date performance to approximately $160 million, with approximately $280 million of opportunities still available to us. Slide 12 has the Q2 order book details versus Q2 of last year. Before M&A, core orders grew 10%. Total orders, including a $62 million contribution for Paragon and Certrec, grew 40% in the quarter to $291 million.

Brian Schopfer
CFO and Medical Group President at Mirion Technologies

Nuclear and safety order growth was driven by the robust growth we saw in the nuclear power end market of approximately 50%, excluding M&A, with half of the dollar growth coming from the operating fleet and the remainder coming from SMRs. The growth within nuclear power was partially offset by declines in labs and research and defense and diversified. Q2 medical orders declined slightly from last year. Recall, we had a tough comp as we prioritized Asia orders to minimize tariff exposure.

Brian Schopfer
CFO and Medical Group President at Mirion Technologies

Dosimetry orders declined due to a tough EUR-based order comp, while nuclear medicine remained flat. Slide 13 details Q2 order performance versus Q1 this year. Recall last quarter, we guided 15%-20% sequential order growth. If we include the two large orders that were awarded in early July, net of the Chinese cancellation, orders grew 14%, slightly below this range. Without the China cancellation, we would have been at the high end of the range. Before digging into the quarterly financial results, first, an update on the nuclear power end market on slide 14. Nuclear power orders, excluding M&A, grew 50% in the second quarter, with both the operating fleet and SMRs being key drivers. We booked $49 million of SMR orders, inclusive of the two large opportunities previously detailed.

Brian Schopfer
CFO and Medical Group President at Mirion Technologies

This is up $42 million over last year, illustrating the continued momentum within the space, as well as Paragon's contribution. Overall, nuclear power revenue was flat organically, with increases in the installed base and SMRs, offset by a decline in new build revenue. We remain confident that nuclear power will see double-digit organic revenue growth for the full year. Let's get into the quarterly financials beginning on slide 15.

Brian Schopfer
CFO and Medical Group President at Mirion Technologies

Consolidated second quarter revenue grew 19.7% to $266.8 million. Approximately 18 of the 19.7% growth was attributed to acquisitions, mainly Paragon. Organic revenue growth of 1% was in line with our April guidance. Second quarter adjusted EBITDA was $65 million or 27.5% better than last year's second quarter. Adjusted EBITDA margins expanded across both segments, with favorable contribution from product mix and pricing. Adjusted EPS totaled $0.12 per share in the quarter.

Brian Schopfer
CFO and Medical Group President at Mirion Technologies

As a reminder, in 2026, we are now including stock-based compensation in our Adjusted EPS calculation. Last year's adjusted EPS would have been $0.09 per share using a similar methodology to the one put in place for 2026. We have an Adjusted EPS reconciliation slide in the appendix that has the details for your modeling. Turning to the nuclear and safety segment on slide 16, second quarter revenue was $186 million, up 31%.

Brian Schopfer
CFO and Medical Group President at Mirion Technologies

Organic revenue was 2.3% in line with our April guidance. We continue to be pleased with Paragon's financial performance, with 15% revenue growth for the quarter and 27% growth year-to-date, highlighting the heightened demand for their products and services. Under Mirion's ownership, we've continued to see Paragon's Adjusted EBITDA margins expand. We expect this trend to continue as we identify and capture further areas of integration and synergy.

Brian Schopfer
CFO and Medical Group President at Mirion Technologies

As previously mentioned, nuclear power end market revenue growth was flat as growth in the installed base in SMRs was offset by less new build revenue in the period. New build revenue can be lumpy based on project timing. Adjusted EBITDA grew 35% to $51 million. Margins expanded approximately 70 basis points, reflecting the impacts of favorable product mix in Europe, good cost control across the business, and a modest tariff refund here in the U.S.

Brian Schopfer
CFO and Medical Group President at Mirion Technologies

This was partially offset by dilution from the Paragon acquisition. On to the medical segment on slide 17. First quarter revenue was $81 million, down 1%. Organic revenue declined 1%, driven by the nuclear medicine and dosimetry end markets. This is below our previously disclosed April expectations of low single-digit organic growth. RTQA revenue continues to grow, driven by the OEM sector performance and our growing software business.

Brian Schopfer
CFO and Medical Group President at Mirion Technologies

We previously mentioned in April that in the second quarter of last year, we shipped a large quantity of products into Asia before tariffs went into effect. Excluding this tariff comp headwind, organic RTQA revenue would have grown mid-single digits. In nuclear medicine, organic revenue declined due to delayed hardware demand. We do expect to see a pickup in the back half of the year in this business.

Brian Schopfer
CFO and Medical Group President at Mirion Technologies

Encouragingly, our nuclear medicine software business generated a strong double-digit order growth in the first half. Lastly, the dosimetry services end market also had negative organic growth. The large hardware order from last year continues to be a difficult comp and will be in the back half of the year as well. Importantly, excluding this, our core dosimetry services organic revenue grew mid-single digits in Q2. Medical segment Q2 Adjusted EBITDA was $31 million, or 3% better than last year.

Brian Schopfer
CFO and Medical Group President at Mirion Technologies

Despite lower revenue, margins expanded in the quarter, reflecting price tailwinds, favorable product mix, and software revenue. We saw limited tariff refunds in this segment. Turning to slide 18, I want to give an update on our end market expectations within medical, while reiterating our full year segment guidance. Within RTQA, we are raising our outlook to double-digit organic growth for the year, up from our prior mid-single digit plus guide, reflecting OEM sector dynamics and continued strong performance from our software offerings.

Brian Schopfer
CFO and Medical Group President at Mirion Technologies

In nuclear medicine, we are lowering our full year guide to mid-single digits, down from our prior double-digit guide, driven by the reduced hardware volume from delayed customer demand. At this point, we see this as a delay, not a decline in demand. In dosimetry, we now expect organic revenue to be negative for the year, down from our prior flat guide, driven by less hardware revenue.

Brian Schopfer
CFO and Medical Group President at Mirion Technologies

Note, we're also lapping the tough comp from hardware sales in 2025. We continue to expect total service revenue growth to be low single digits plus, in line with historical guidance. These puts and takes largely offset, and we are maintaining our full year medical segment guidance. Turning to adjusted free cash flow on slide 19. We generated $49 million of adjusted free cash flow in Q2 to end the first half of 2026 with $60 million of adjusted free cash flow. This improvement represents our best first half adjusted free cash flow since going public and is driven by good control of our net working capital with continued improving metrics, lower cash taxes, and improvements to our capital structure. Turning to slide 20, our full year 2026 guidance is unchanged from April.

Brian Schopfer
CFO and Medical Group President at Mirion Technologies

Based on what we discussed earlier around our backlog coverage, slide 21 shows that we're expecting to see an uptick in the second half of the year. On organic revenue growth, the first half came in at 2%, held back by difficult comparables from last year's tariff related pull forward on the Medical side and a difficult Q1 2025 Nuclear Power comp. We expect organic revenue to step up meaningfully in the back half to between 7.5%-11.2%, driven by the Nuclear and Safety end market within Nuclear and Safety and the RTQA end market within. On margins, first half adjusted EBITDA margins came in at 22.8%, down 23 basis points year-over-year on dilutive M&A and mix impacts from Q1 2026.

Brian Schopfer
CFO and Medical Group President at Mirion Technologies

As is seasonally normal, we expect to see acceleration on margins in the second half of the year, with margin rates expected to be between roughly 27%-29%, up roughly 150 basis points versus last year as operating leverage kicks in. Second half adjusted free cash flow is forecasted at $95 million-$115 million, with Q1 having been our lightest quarter, and Q4 will be our largest cash generation quarter. At this point, we're trending towards the high end of the range. Accelerating organic growth and expanding margins, coupled with strong backlog are why we remain confident in our full year guidance despite a slower first half. Before we open the call to Q&A, let's spend some time discussing the third quarter guidance on slide 22. Consolidated third quarter organic revenue growth is expected to be in the high single digits.

Brian Schopfer
CFO and Medical Group President at Mirion Technologies

Nuclear and Safety is expected to be mid-single digits, while we anticipate high single-digit growth in Medical. Consolidated adjusted EBITDA margins are expected to expand compared to last year. Nuclear and Safety segment adjusted EBITDA margins should contract, reflecting the impacts of the dilution from Paragon, comping a reduction in incentive compensation for 2025, and the mix shift impact of anticipated higher new build revenue in the quarter. As a reminder, new build projects typically have a slightly lower margin than the installed base. Medical segment adjusted EBITDA margins are expected to expand due to the impact of operating leverage from increasing revenue growth versus the first half of the year. With that, we're happy to take your questions.

Operator

Thank you. We will now be conducting a question and answer session. If you would like to ask a question, please press star one on your telephone keypad. A confirmation tone will indicate your line is in the question queue. You may press star two if you would like to remove your question from the queue. For participants using speaker equipment, it may be necessary to pick up your handset before pressing the star keys. One moment please while we poll for questions. Our first question is from James West from Melius Research. Please go ahead.

James West
James West
Analyst at Melius Research

Hey, good morning, Tom and Brian.

Brian Schopfer
CFO and Medical Group President at Mirion Technologies

Thanks. Good morning, James.

James West
James West
Analyst at Melius Research

Curious about what you guys talk about is your large opportunity pipeline. There's a significant amount of potential out there that you've discussed. A lot of it's still available, as you noted in your slide deck and in your comments in this year, but also as we go into 2027. I wanted to just, if you could characterize a bit for us, how much of that potential, I guess, is kind of yours to lose, if you will, or follow on contracts? How much is that definitely coming to Mirion? How much is up for grabs for others? Just curious if you have some kind of view on how much we should be thinking about that translating to Mirion.

Tom Logan
Tom Logan
Chairman and CEO at Mirion Technologies

James, I'll start and then Brian can add additional color. The way we look at it is that we've got a right to win on all of this stuff. The screening methodology that we use here, just again, to provide this color, this broader visibility, is that these are opportunities that are greater than $10 million in scope, where we think, again, our probability of winning is likely to be greater than 50%, meaning that, again, we feel like we've got a right to win.

Tom Logan
Tom Logan
Chairman and CEO at Mirion Technologies

I think if we look at the opportunities that actually traded in the last quarter, I believe we won all of them. I don't think we lost anything that actually transacted over that period of time. We remain optimistic about our ability to continue that track record. In our view, in general, the biggest risk is timing risk, where depending on the nature of the project, the sector that it's in, et cetera, they can have a tendency to move to the right. I'd also note that this is a replenishing opportunity set that continues to build overall. We feel very good about it in aggregate.

James West
James West
Analyst at Melius Research

Right. Okay. That makes perfect sense. Then, maybe just a little bit unrelated follow-up, though. When I was with you earlier, when we were traveling earlier this year, we talked about the M&A outlook, and you were very clear that you had a pipeline, and it was strong. I wonder, I'm just curious if that has any change there, or should we be expecting announcements? What's happening with the target list?

Tom Logan
Tom Logan
Chairman and CEO at Mirion Technologies

I would characterize our M&A pipeline as one of continued strength. There are a lot of really interesting assets in the market that we view as being highly complementary strategically to our business model. This M&A, to be clear, has always been an important part of our strategy. We've done roughly 20 deals over the last decade, our expectation is that we're going to continue to be active in this realm.

James West
James West
Analyst at Melius Research

Got it. Great. Thanks, Tom.

Operator

Our next question is from Joe Ritchie with Goldman Sachs. Please proceed with your question.

Joe Ritchie
Joe Ritchie
Analyst at Goldman Sachs

Hey, guys. Good morning.

Tom Logan
Tom Logan
Chairman and CEO at Mirion Technologies

Morning.

Joe Ritchie
Joe Ritchie
Analyst at Goldman Sachs

You guys provided a bunch of good color on the confidence you have in the guide going into the rest of the year. I guess maybe if you're just thinking about the Nuclear and Safety segment, I think the implied guidance implies at least mid-teens type organic growth in the fourth quarter. I just want to get a sense for how much of that is already in backlog, and then maybe just provide a little bit more color on that ramp between now and the end of the year.

Brian Schopfer
CFO and Medical Group President at Mirion Technologies

I think this is why we kind of gave a pretty implicit Q3 guide because you can now squeeze it to the fourth quarter. I think your math is right. I think we put the visibility out there kind of for the rest of the year. We put it in totality, 81%. We're sitting kind of exactly where we sat at this point in every other quarter coming out of Q2. A reminder, when we look backwards, we're talking about where we actually landed from a revenue perspective over what we thought would trade from a backlog perspective. It's a pretty apples to apples comparison. We put out the guide. We feel very good about where we are. We have good visibility to the back end of the year.

Brian Schopfer
CFO and Medical Group President at Mirion Technologies

There's clearly some wood to chop, both on the execution side, we still have orders to win. I think the orders that we won in early July also help us along the way. We continue to feel good about where we sit, Joe, we recognize that a mid-teens guide for the fourth quarter is big. I would also tell you the comps for us more broadly in the back half of the year are smaller than what we saw kind of in the first half of the year, I think that gives us a tailwind there, too.

Joe Ritchie
Joe Ritchie
Analyst at Goldman Sachs

That's helpful, Brian. Maybe just a broader question for Tom. Just talking about that China de-booking. I know it was only $18 million, it was for a contract that went all the way back to 2019. Can you just kind of maybe just talk about how you guys think about the backlog that you have today, like whether there's any potential risk from some of these legacy contracts? Why now to de-book that specific contract this quarter?

Tom Logan
Tom Logan
Chairman and CEO at Mirion Technologies

Joe, we continuously scrutinize our backlog, as you're aware, the history of de-booking events for us is exceedingly rare. These are very unusual events typically tied to some broader issue. Shortly after we went public, we had de-booking of a Finnish order that was tied to the Ukraine conflict. We had a de-booking in Turkey a couple of years later that was related to a, what I would call, characterized as a localized contractual dispute. This one came, candidly, a bit out of the blue. To be clear, when you look at the contractual provisions, there is not an exit provision, obviously, we will have extensive discussions and negotiations in and around this. Having said all of that, this was a contract that essentially was undergirded by a project that was making very little progress.

Tom Logan
Tom Logan
Chairman and CEO at Mirion Technologies

It is a contract that was booked many years ago and has candidly been impacted by some of the changed trading dynamics, specifically between the U.S. and China. Looking beyond that, when we look at our backlog quality, our view is it continues to be very high. We don't see any level of elevated risk. We don't see this as being some kind of trigger event where there are others that fall behind us and, again, remain confidence in the dry powder that we have there overall. The other thing I would note, you didn't ask this, Joe, but just to note it, when we look at the Chinese market overall and recognize that today, if you look at our position in the installed base, we have a meaningful position in 50 out of 60 operating Chinese reactors.

Tom Logan
Tom Logan
Chairman and CEO at Mirion Technologies

This is an experiential track record that candidly even predates Mirion. It goes back about 30 years. We've been a longstanding fixture in this market. We've also been very clear that over time, over those decades, we have seen a declining wallet share overall in the Chinese market, driven by factors that are familiar in every industry. Importantly, where we stand today, we continue to see what I would characterize as a robust and predictable spare parts market. There, again, recognizing that position in 50 reactors in China, that if you look back over the last five years, has been averaging about $8 million a year. We have confidence that that will continue. Moreover, when we look at new build dynamics, there are two primary streams, and I'd argue a third stream of lesser importance in Chinese new build activity.

Tom Logan
Tom Logan
Chairman and CEO at Mirion Technologies

The primary focus now is on an indigenous reactor type called the Hualong reactor, where essentially we are locked out. We have no content in that. The planned feature of the Hualong is that it is 100% indigenous, locally produced Chinese reactor. To be clear, there continue to be export opportunities in China through derivatives of the Westinghouse AP1000 technology, the Framatome EPR technology, and the Rosatom VVER opportunity. We expect that we're going to continue to have at-bats there, and that will continue over our planning horizon.

Tom Logan
Tom Logan
Chairman and CEO at Mirion Technologies

Final thing I'd say about China too is that right now we are very active in three advanced reactor applications in China. China is very active in the SMR market overall and doing some really interesting things with advanced reactor technology, and that continues to be an opportunity for us overall. This de-booking was disappointing. There'll be more to the story that will play out over the next few months, but we don't view it as auguring some broader set of issues for us.

Joe Ritchie
Joe Ritchie
Analyst at Goldman Sachs

Yes, thanks for the detailed explanation, Tom. Appreciate it.

Operator

Our next question is from Quinn Fredrickson with Baird. Please proceed with your question.

Quinn Fredrickson
Quinn Fredrickson
Analyst at Baird

Hi. Good morning, guys.

Tom Logan
Tom Logan
Chairman and CEO at Mirion Technologies

Good morning.

Quinn Fredrickson
Quinn Fredrickson
Analyst at Baird

Just building on that last question on SMRs. You clearly have some momentum here based on these large orders and then expecting a move from 2% of revenue to 3% through this year. I think 2030 has been speculated as the timeframe when SMRs become more commercially deployed. Just based on that order momentum and the visibility you have today, should we think about the portion of your revenue from SMRs scaling further in 2027?

Tom Logan
Tom Logan
Chairman and CEO at Mirion Technologies

What I would say, Quinn, is that the continuing theme here is that while historically we have been very cautious about expressing confidence in the SMR timeline overall, the reality continues to move to the left. We are seeing a stronger and stronger opportunity flow in this sector. Our positioning here is somewhat unique when you look at the breadth of our capabilities that are relevant to these players overall.

Tom Logan
Tom Logan
Chairman and CEO at Mirion Technologies

Our view is that the growth dynamic, without putting specifics on guidance here, but our view is that the growth opportunity here is considerable, and the momentum is continuing to build. We are increasingly bullish on this sector. We are increasingly bullish on our positioning, our right to win, if you will. While I'm not necessarily going to call the ball now, I do expect this is going to continue to grow at a rate faster than our overall organic growth rate for the rational planning horizon.

Quinn Fredrickson
Quinn Fredrickson
Analyst at Baird

Thanks, Tom. For my follow-up on nuclear medicine, can you just elaborate on what caused the reduced hardware volume and delayed demand during the quarter, and then unpack what gives you confidence in the pickup in the back half that you mentioned?

Brian Schopfer
CFO and Medical Group President at Mirion Technologies

Yeah. I think we've just seen a bit of a pause, I think, in the first half. I think we're waiting to see some more momentum in the drug pipeline. The team continues to be very bullish about the second half, just on what we saw kind of coming out of June. Our nuclear medicine software business saw very strong order growth in the first half of the year. I think I talked about double digits, and it was a strong double digits, for what it's worth.

Brian Schopfer
CFO and Medical Group President at Mirion Technologies

We've spent a lot of time in that factory. If you remember, we did an ERP implementation there. We've consolidated some factories there. That factory is absolutely working better today than it has been, lead times have come down dramatically. Our ability to kind of book and ship in that business in a quarter, in two quarters, has dramatically increased. I think all those dynamics are at play here. This is one we continue to watch, but it's one we continue to be optimistic about as we come through the back end of the year into 2027.

Quinn Fredrickson
Quinn Fredrickson
Analyst at Baird

Thanks.

Operator

Our next question is from Andy Kaplowitz with Citigroup. Please proceed with your question.

Andrew Kaplowitz
Andrew Kaplowitz
Analyst at Citigroup

Good morning, everyone. Thanks for all the detail.

Brian Schopfer
CFO and Medical Group President at Mirion Technologies

Good morning, Andy.

Andrew Kaplowitz
Andrew Kaplowitz
Analyst at Citigroup

Tom or Brian, I just wanted to sort of ask Joe's question in a slightly different way. Nuclear power order growth of 47% ex M&A, but as you know, nuclear power revenue was still flat-ish in Q2. Why has the disconnect between the two lasted so long here? If I think about what's ramping up in Q3, I know you said you're starting to lap much easier comparisons in your nuclear. Is it that simple, or is there maybe higher degree of SMR as well as installed base projects that's ramping up, too? Have you seen any inflection so far here in July?

Brian Schopfer
CFO and Medical Group President at Mirion Technologies

Look, in order to hit the back-end numbers, I think we're expecting a step-up kind of in all three pieces of the nuclear power business, SMR, new build, and NPP. Just as a reminder, NPP is 80% of our nuclear power revenue. Obviously, to hit the back end of the numbers, we need to see that business work. I think I put some comments in my script, Andy, that the nuclear power growth was very good, and it was half on a dollars basis out of the installed base and half out of the SMR space, which you can see much of the SMR stuff came via the large orders. I think that continues to give us confidence that business is poised to be able to deliver in the back half of the year.

Brian Schopfer
CFO and Medical Group President at Mirion Technologies

Again, Joe asked specifically about Q4, more broadly, we're sitting at a coverage base that at the midpoint of our guide is the same as where we sat every year, basically, for the last couple of years. I would tell you, if you added the Paragon's revenue, that gives you another incremental percentage point of coverage for what it's worth on the back end. Plus, the wins we saw in early July, although it won't be a lot of revenue that kind of comes through the P&L, that continues to bolster our coverage dynamics. Hopefully that's a little bit more color that kind of helps give you confidence.

Andrew Kaplowitz
Andrew Kaplowitz
Analyst at Citigroup

Very helpful. Tom, maybe just big picture. I think over the last couple of quarters, there's been a little bit more fear in the market that the proliferation of let's call it short-cycle power supply will somehow impact the nuclear cycle. Maybe, you talk to a lot of customers, what are you hearing? Are customers at all disturbed about that? What do you think your customers' confidence level is that when they get to finish line on these longer cycle nuclear projects, that there'll be enough out there for them? Just your opinion.

Tom Logan
Tom Logan
Chairman and CEO at Mirion Technologies

Yeah. I think from a contextual standpoint, Andy, I think there's a broader belief that may be a little bit erroneous that we are fundamentally locked into the data center build-out cycle. While clearly new data centers is the biggest call on incremental energy demands in both regulated and deregulated markets overall, we see it as being a bit more binary. By that, what I mean is that, again, take a point historically, five years ago, more pointedly 10 years ago, when the operators of nuclear power plants were really struggling economically. As a result, we're in extreme capital rationing modes, really trying to ratchet down on OpEx, et cetera. Today it's a vastly different picture.

Tom Logan
Tom Logan
Chairman and CEO at Mirion Technologies

Even if the rate of data center builds slows dramatically, effectively, they've made a binary decision that I want to extend the life of my asset base by another 20 years. That's the big trigger for us. Once that decision is made, it drives an attendant requirement to invest in numerous systems and subsystems that in many cases have replacement cycles of a decade, In some cases even two decades overall. Firstly, the generalized fear about both supply side and demand side dynamics when you look at the nuclear base, I think have less impact on us overall. Again, because the key decisions are, I want to extend the life of my power plant and in the wake of that, I want to operate the capacity.

Tom Logan
Tom Logan
Chairman and CEO at Mirion Technologies

Remembering that 80% of our revenue comes from the global installed base, I think that's the most important foundational belief, foundational understanding that people need to have when they think about our business. At the margin, more data centers clearly means more incremental generating capacity with probably the small modular reactor market experiencing the greatest alpha as it relates to that overall. To us, we view that as upside. We view that as optionality and a good deal less important than the growth arc of that installed base.

Andrew Kaplowitz
Andrew Kaplowitz
Analyst at Citigroup

Very helpful.

Operator

Our next question is from Chris Moore with CJS Securities. Please proceed with your question.

Chris Moore
Chris Moore
Analyst at CJS Securities

Hey, good morning, guys. Maybe talk a little bit about margin. Obviously the Paragon acquisition continues to be really attractive. Just wondering if it makes the 30% EBITDA target for 2028 a little more challenging, just for context. I mean, 2025 margin is 24.6%. I think midpoint of this year guide is 25.6% on your basis point increase. Consensus for next year is 27.1%, so it's about 150 basis point increase. Either there needs to be a 300 basis point spike from 2027 to 2028 or the 2027 estimates are too low. I guess, the question really is, am I looking at that correctly? And what are the puts and takes in terms of the EBITDA margin increase to be incrementally much more in 2027 versus 2026 and perhaps again in 2028?

Tom Logan
Tom Logan
Chairman and CEO at Mirion Technologies

Yeah. Chris, just to begin at a high level and talk about the major building blocks that walk us up that, essentially that 4.5 points of go get, if you take the midpoint of the guide on year-end 2026 EBITDA margins and that 25.5 point range overall. As we've talked about extensively in the past, the biggest building block for us is operating leverage. We have a high degree of operating leverage given the fixed versus variable cost spread that we have. What that means at the margin is that our contribution margins are higher than our gross margins, and if we can maintain discipline on our factory overhead and our SG&A growth, we'll see a greater component of fall through.

Tom Logan
Tom Logan
Chairman and CEO at Mirion Technologies

If you sketch that forward, we would anticipate that half or more of that go get simply comes from operating leverage as the top line continues to grow. The second major component for us is procurement. We've made meaningful gains in our procurement efficiency and the associated cost dynamics over the last two years, but we still have a strong queue of in-stream opportunities that really reflect kind of a multi-year prosecution of a more optimized state in our supply chain. Our view is that that's another one to two points of margin over this period of time, just based on what we have line of sight to today and again, what is in our queue. The final piece of it really is kind of the self-help stuff beyond procurement.

Tom Logan
Tom Logan
Chairman and CEO at Mirion Technologies

It is the application of our business system, which now is further enabled by what we're doing with AI for internal productivity. Here, it's many, many different things. It's improving our conversion efficiency, it's improving sales and operational planning. It's continued optimization of our factory footprint, recognizing that we, in general, have more capacity than we need. It's improvement of all the administrative SG&A related workflows, et cetera. To that end, again, if you had a glimpse of our hierarchy of priorities, again, we have confidence that there is a significant queue of opportunities.

Tom Logan
Tom Logan
Chairman and CEO at Mirion Technologies

A footnote to all of that is that in the quarter we took a reserve for some organizational restructuring that is in stream right now that essentially is driven by an opportunity for us in the near term here to continue to evolve and improve the efficiency of our organization as we look at spans and layers, other dynamics that is going to add more of a near-term benefit on the margin rate as we look ahead to 2027 overall. We're still holding to a 30-point target. To be clear, that's an audacious target. It's one that we are very motivated to achieve. Notwithstanding the dilutive impacts of some of the M&A deals that we've done, we're eyes open about it.

Chris Moore
Chris Moore
Analyst at CJS Securities

Got it. Very helpful. Maybe just a quick follow-up on, you talked quite a bit about on the AI side. Just wondering, is there a significant amount spend at this point in time on the AI or is there much anticipated to get to where you need to go?

Tom Logan
Tom Logan
Chairman and CEO at Mirion Technologies

For us right now, as we continue to build our AI capabilities organizationally, and here it's a combination of data infrastructure and building out the engineering capabilities, and then on top of that, it's token spend overall as a company. Right now our spend rate, and this is from a cash standpoint, most of this is OpEx, some of this CapEx, is running about $5 million. It's a number that is growing and obviously a number that we're mindful of when we think about margin dynamics overall. It's not an outrageous number, but it is a material number.

Chris Moore
Chris Moore
Analyst at CJS Securities

Got it. Helpful. Again, I will leave it there.

Operator

Our next question is from Jeff Grampp with Northland Capital Markets. Please proceed with your question.

Jeff Grampp
Jeff Grampp
Analyst at Northland Capital Markets

Morning, guys.

Tom Logan
Tom Logan
Chairman and CEO at Mirion Technologies

Hey, Jeff.

Jeff Grampp
Jeff Grampp
Analyst at Northland Capital Markets

Was curious to touch on the 2027 pipeline, large opportunity pipeline. I think you guys noted in the slides that that's building or growing. I'm just curious, today versus this time last year, now that we kind of know how the 2026 pipeline shook out, any observations, compare and contrasts or themes worth noting at this point? Understanding it's still a bit early to know anything too definitively.

Tom Logan
Tom Logan
Chairman and CEO at Mirion Technologies

Yeah, Jeff, I think the biggest delta just thematically between today and a year ago is the SMR opportunity set, which again, as I noted, we are seeing a lot of tangible engagement here. The opportunity set related to new build activity in the SMR arena continues to build. On top of that, we do see meaningful gigawatt scale opportunities and then an assortment of other opportunities relating to federal government work and global analogs for that is broadly in line with what we saw a year ago. The biggest delta would be on the new build front, and most pointedly in the SMR arena.

Jeff Grampp
Jeff Grampp
Analyst at Northland Capital Markets

Great. I appreciate those details. My follow-up, more near term on the Q3 commentary you guys had. Nuclear and Safety, I think you were looking mid-single-digit growth, and then within that power, specifically double-digits. I guess implying some of the other contributing factors are a bit slower or lower. Is that isolated to Q3, or can you just touch on those dynamics a bit for the other kind of revenue buildups within the Nuclear Safety segment? Thanks.

Brian Schopfer
CFO and Medical Group President at Mirion Technologies

Yeah, I think you have the math right. I think we haven't changed a lot of our full year guides on the Nuclear and Safety side from an end market standpoint. We continue to think labs or we continue to model at least, and we'll see how it plays out. Labs and research will be flat for the year. The diversified business will kind of be mid-single digits-ish. The nuclear power business, as we commented, is double digits. Obviously the math stated earlier in the Q&A about the fourth quarter kind of teens number implies that the Nuclear and Safety Business is a big piece of that. I don't really have anything other to add than that at this time.

Jeff Grampp
Jeff Grampp
Analyst at Northland Capital Markets

Okay. Fair enough, Brian. Appreciate the time, guys. Thank you.

Operator

Our next question is from Tomo Sano with JPMorgan. Please proceed with your question.

Tomo Sano
Tomo Sano
Analyst at JPMorgan

Hi. Good morning, everyone.

Tom Logan
Tom Logan
Chairman and CEO at Mirion Technologies

Hi, Tomo.

Brian Schopfer
CFO and Medical Group President at Mirion Technologies

Good morning, Tomo.

Tomo Sano
Tomo Sano
Analyst at JPMorgan

Thank you for taking my question. On July net bookings were $37 million. Could you give us more color, major contributors? Should we think about this as run rate or timing related? If you could share more color into the second half, appreciate it. Thank you.

Brian Schopfer
CFO and Medical Group President at Mirion Technologies

Just to clarify, the $37 million net is just the two large orders we won in the first two weeks of July and the Chinese cancellation that we've already talked about. That doesn't include anything broader from a sub-10 million order scale or kind of the book-to-bill business.

Tomo Sano
Tomo Sano
Analyst at JPMorgan

Okay. Brian, if you could talk about some opportunities and momentums into our second half for large opportunity pipeline, appreciate it.

Brian Schopfer
CFO and Medical Group President at Mirion Technologies

You could see it on the right side of that slide. We still largely have about 12 opportunities in Q. Eight are, we would classify in the new build, so that's both utility scale and SMR. You can see noted, we haven't done this before, but that represents about 15 reactors in there. It's obviously not one-to-one. Again, as Tom mentioned, we like our right to win on every one of those. The timing dynamic between Q3 and Q4, look, I got burned on that in the second quarter, so I'm not going to try to pin it again in the third quarter. We continue to believe each and every one of these opportunities should and could trade this year. We'll see how that plays out. Obviously, we continue to see a couple things in the install base of size.

Brian Schopfer
CFO and Medical Group President at Mirion Technologies

I would tell you, there's less $10 million-plus projects in the install base on a size basis. The DOE, I would say, represents kind of that last bucket. We continue to see very good activity on the pipeline side out of the DOE. That's something we're watching on whether that kind of hits us here in 2026 or maybe 2027. Obviously, we're watching the government shutdown dynamics closely too in Washington. A lot happening. We continue to believe there's a lot out there for us, kind of on the larger scale stuff. That flow business continues to have good momentum.

Tomo Sano
Tomo Sano
Analyst at JPMorgan

Thank you. Just one quick follow-up on the capital allocations. As you generate stronger free cash flow and target lower leverage, how are you thinking about the medium-term capital allocations? I think it's Tom, you mentioned about the AI investment and some of the opportunity M&A. Brian, you talked about buybacks. Any update? Appreciate it. Thank you.

Tom Logan
Tom Logan
Chairman and CEO at Mirion Technologies

Tomo, if we did no M&A for the balance of the year, looking at our operating plans and our capital spending plans, we'd end the year at about two and a half times leverage, somewhere in that range. Again, we've got a decent pipeline within that. These tend to be smaller-sized deals. Our first priority strategically, as we think about capital allocation generally, is M&A, but there will invariably be a net reduction in leverage over the course of the year, and the degree to which that's impacted by M&A is TBD.

Tomo Sano
Tomo Sano
Analyst at JPMorgan

Thank you. I appreciate it. That's all.

Operator

We have reached the end of the question and answer session. I would like to turn the floor back over to Tom Logan for closing remarks.

Tom Logan
Tom Logan
Chairman and CEO at Mirion Technologies

Ladies and gentlemen, appreciate your time and attention today. Again, we're happy to report the second quarter performance. Obviously, excited about the support that we have for Q3 and Q4, and look forward to reconnecting in three months to update our outlook at that point in time. Appreciate your time. Thank you.

Operator

This concludes today's call conference. You may disconnect your lines at this time. Thank you for your participation.

Executives
    • Eric Linn
      Eric Linn
      Treasurer and Head of Investor Relations
    • Tom Logan
      Tom Logan
      Chairman and CEO
Analysts
Powered by Quartr